Post-COVID mRNA vaccine myocarditis in children: report of two cases.

Shamekh, Ahmed; Powell, Colin; Ashabani, Abdusamea; Abdelgadir, Ibtihal Siddiq

Shamekh, Ahmed; Powell, Colin; Ashabani, Abdusamea; Abdelgadir, Ibtihal Siddiq.

Shamekh A; Paediatric Emergency, Sidra Medicine, Doha, Ad Dawhah, Qatar ashamekh@hotmail.com.
Powell C; Paediatrics, Cardiff and Vale University Health Board, Cardiff, UK.
Ashabani A; Paediatric Emergency, Sidra Medicine, Doha, Ad Dawhah, Qatar.
Abdelgadir IS; Paediatric Emergency, Sidra Medical and Research Center, Doha, Qatar.

BMJ Case Rep ; 15(11)2022 Nov 28.

Article in English | MEDLINE | ID: covidwho-2137570

ABSTRACT

ABSTRACT

The SARS-COV-2 pandemic led to the development of several vaccinations to contain the disease. The Pfizer-BioNTech COVID-19 (BNT162b2) vaccine was recommended on May 2021 for use in children above 12 years and older. The vaccine is safe, well tolerated and highly effective. Initial reports showed no serious adverse events; however, cases of myocarditis in young healthy male adolescents have been reported. We report two cases of myocarditis/perimyocarditis who presented with short history of chest pain following administration of the second dose of the MRN COVID-19 vaccine.

Subject(s)

BNT162 Vaccine; COVID-19; Myocarditis; Adolescent; Child; Humans; Male; BNT162 Vaccine/adverse effects; COVID-19/prevention & control; Myocarditis/chemically induced; SARS-CoV-2

Keywords

COVID-19; Cardiovascular system; Paediatrics (drugs and medicines); Vaccination/immunisation

Fulltext

XML

PubMed Links

Search on Google

Full text: Available Collection: International databases Database: MEDLINE Main subject: COVID-19 / BNT162 Vaccine / Myocarditis Type of study: Case report / Observational study / Prognostic study Topics: Long Covid / Vaccines Limits: Adolescent / Child / Humans / Male Language: English Year: 2022 Document Type: Article Affiliation country: Bcr-2022-253383

Similar

MEDLINE

LILACS

LIS

Fulltext

XML

PubMed Links

Search on Google